Niagen (nicotinamide riboside) / Niagen Bioscience - LARVOL DELTA

Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review. (PubMed, Clin Interv Aging) - "Combinations such as dasatinib plus quercetin and the flavonoid fisetin have reduced circulating SASP factors in early studies. Senomorphic agents, including rapamycin and Janus kinase (JAK) inhibitors, represent an alternative strategy by suppressing SASP production while preserving cell viability...Supplementation with precursors such as nicotinamide riboside and nicotinamide mononucleotide has shown beneficial effects on vascular function and metabolic health in early human studies...Repurposed metabolic medications including metformin, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists also exhibit anti-inflammatory effects...Despite progress, translating these findings into clinical practice remains challenging because validated biomarkers are limited, trial designs are complex, and long-term safety data are still needed. Future collaborative research will help evaluate combination strategies and precision approaches targeting..."

First-in-human • IO biomarker • Journal • Review • Cardiovascular • Inflammation • IL1B • IL6 • TNFA

Adipose ILC2s depend on acetyl-CoA carboxylase 1 to maintain metabolic health. (PubMed, Cell Metab) - "Supplementing with the NAD+ precursor nicotinamide riboside rescues ACC1 deficiency, restoring ILC2 function and adipose tissue homeostasis. These findings establish ACC1 as a critical regulator of adipose ILC2 maintenance and function and provide a rationale for the adverse effects of ACC inhibition in obesity."

Journal • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity

Metabolism of Nicotinamide Adenine Dinucleotide+ in Atherosclerosis: Mechanisms and Nutritional Modulation. (PubMed, Nutr Rev) - "By integrating vascular biology with nutrition-based modulation strategies, this review provides a practical conceptual framework for interpreting current evidence and guiding future research. Well-designed trials incorporating vascular-specific biomarkers and clinically meaningful cardiovascular endpoints are needed to determine the therapeutic relevance of NAD+-targeted nutritional interventions."

Journal • Atherosclerosis • Cardiovascular • Inflammation

Diabetes-Associated Enteric Neuropathy: An Overlooked Driver of Gastrointestinal Dysfunction. (PubMed, J Vis Exp) - "Heme oxygenase-1, interleukin-10, neurotrophic rescue, nicotinamide riboside, 5-hydroxytryptamine 4 receptor agonism, microbiota-derived butyrate, and extracellular vesicles are investigational rather than established disease-modifying therapies. Segment-specific biomarkers and human translational models are needed to connect cellular injury with symptoms and treatment response."

Journal • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Pain • HMOX1 • IL10

Effects of Single-Dose Nicotinamide Riboside (NR) on Sleep (clinicaltrials.gov) - P=N/A | N=28 | Completed | Sponsor: Eye & ENT Hospital of Fudan University | Not yet recruiting ➔ Completed | N=20 ➔ 28 | Trial completion date: Dec 2026 ➔ Sep 2026 | Trial primary completion date: Dec 2026 ➔ Aug 2026

Enrollment change • Trial completion • Trial completion date • Trial primary completion date

SUNRISE: Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants (clinicaltrials.gov) - P2/3 | N=40 | Recruiting | Sponsor: University of California, Davis | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2026 ➔ Aug 2027 | Trial primary completion date: Jun 2026 ➔ Aug 2027

Enrollment open • Trial completion date • Trial primary completion date

Neuroprotective impact of nicotinamide riboside and metformin on the hippocampus of male rats with diet-induced obesity. (PubMed, Metab Brain Dis) - "NR and metformin were associated with beneficial effects on obesity-related hippocampal alterations, accompanied by favourable changes in apoptosis-related, metabolic, and neurotrophic gene expression as well as improved stereological indices of hippocampal integrity. The combined treatment generally produced greater improvements than either monotherapy. These findings support further investigation of NR and metformin as potential interventions for obesity-associated hippocampal dysfunction and cognitive impairment."

IO biomarker • Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Genetic Disorders • Metabolic Disorders • Obesity • BAX • BCL2 • CASP3 • PPARGC1A • SIRT1

Early life high-fat diet exposure modulates adult metabolic phenotypes in Drosophila. (PubMed, iScience) - "Targeted adult interventions with the NAD+ precursor nicotinamide riboside, the TCA intermediate α-ketoglutarate, or commensal bacteria (Acetobacter and Lactobacillus spp.) restored mitochondrial redox balance, improved respiratory capacity, and extended lifespan. Together, these findings identify mitochondrial dysfunction and microbial remodeling as enduring features of developmental dietary lipid stress and suggest that this metabolic state remains partially reversible through mitochondrial and microbiota-directed interventions."

Journal • Metabolic Disorders

Comparative metabolomic profiling reveals salinity tolerance mechanisms in a rice introgression line. (PubMed, Metabolomics) - "Comparative analysis identified differentially accumulated metabolites (DAMs) spanning diverse chemical classes, including amino acids, sugars and carbohydrates, lipids, organic acids, cofactors, electron carriers, and nucleotides. Under salt stress (SS), 201 DAMs (89 upregulated and 112 downregulated) were detected in JN relative to JU. Notably, metabolites such as allantoin, glycitin, nicotinamide ribotide, D-arabinono-1,4-lactone, violanthin, L-methionine S-oxide, ribitol, lysine, rutin, glutamine, pantothenic acid, and quinic acid, showed significant differential accumulation. Pathway enrichment analysis revealed significant enrichment of arginine biosynthesis, purine metabolism, and alanine, aspartate, and glutamate metabolism, indicating extensive reprogramming of nitrogen and energy-associated metabolic pathways under salinity stress. Integration of transcriptomic and metabolomic datasets from the SS experiments further identified ten differentially expressed..."

Clinical • Journal

Pharmacological Management of Diabetic Neuropathy: Current Evidence, Clinical Positioning, and Emerging Therapeutic Targets. (PubMed, Curr Neuropharmacol) - "Managing diabetic neuropathy necessitates personalized treatment that equilibrates analgesia with tolerability. Current medications primarily alleviate symptoms; however, ongoing investigations into antioxidant and neuroprotective agents present the potential for therapies that may decelerate or reverse nerve damage."

Journal • Addiction (Opioid and Alcohol) • Anesthesia • Diabetes • Diabetic Neuropathy • Inflammation • Metabolic Disorders • Neuralgia • Pain

Severe acute poisoning with methadone and α-pyrrolidinovalerophenone complicated by circulatory arrest (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Additionally, antibacterial therapy was employed, along with measures to resolve intestinal obstruction. Following stabilization of the blood's oxygen transport function, a multicomponent drug containing inosine, nicotinamide, riboflavin, and succinic acid was used, which facilitated correction of hypoxic complications and the acute psycho-organic syndrome, leading to improvements in cognitive function."

Journal • Cardiovascular • CNS Disorders • Cognitive Disorders • Critical care • Depression • Gastrointestinal Disorder • Hepatology • Metabolic Disorders • Psychiatry • Renal Disease • Respiratory Diseases

Nicotinamide Adenine Dinucleotide and Its Anti-aging Effects in the Context of Longevity and Menopause. (PubMed, Mini Rev Med Chem) - "The review was developed using PubMed, Scopus, and Web of Science databases, considering studies associated with menopause, aging, NAD⁺ metabolism, nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), mitochondrial dysfunction, and inflammatory signaling pathways...However, despite the important mechanistic advances achieved in recent years, long-term clinical evidence is still insufficient to support a definitive therapeutic conclusion. Therefore, more experimental and clinical studies are still required to establish the real therapeutic relevance and safety of NAD⁺-targeted interventions in menopausal women."

IO biomarker • Journal • CNS Disorders • Inflammation • Metabolic Disorders • Women's Health

NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria. (PubMed, Cell Rep) - "We investigated effects of nicotinamide riboside (NR) supplementation for "mutator" mice manifesting mitochondrial progeria...These findings indicate that while beneficial for heart, chronic NAD+ boosting can compromise erythrocyte maturation in the context of mitochondrial disease. The data emphasize importance of evaluating systemic effects of NAD+ boosting therapies beyond the primary affected tissues and development of tissue-specific metabolic interventions for degenerative diseases."

Journal • Cardiomyopathy • Cardiovascular • Hematological Disorders • Metabolic Disorders

Age-Dependent Progression of Neurological Involvement in PRPP Deficiency: Insights from a Four-Generation Family and Systematic Review. (PubMed, Biomolecules) - "Ultimately, DFNX1, CMTX5, and Arts syndrome represent a continuous PRPS1-related neurometabolic spectrum. Because targeted metabolic interventions (such as S-adenosylmethionine or nicotinamide riboside) have limited efficacy on advanced structural nerve damage, recognizing this early diagnostic window to initiate biochemical rescue prior to irreversible axonal degeneration is critical."

Journal • Review • CNS Disorders • Genetic Disorders • Metabolic Disorders • Ophthalmology • Otorhinolaryngology • PRPS1

Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling. (PubMed, Cells) - "Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis. This finding supports the potential of NR as an adjunctive strategy for mitigating cisplatin-associated hepatorenal injury and warrants further preclinical and clinical investigation."

Journal • Dyslipidemia • Metabolic Disorders • Renal Disease • KIM1 • NQO1

MINIRICO: Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid (clinicaltrials.gov) - P2 | N=310 | Completed | Sponsor: University Hospital, Akershus | Active, not recruiting ➔ Completed

HEOR • Trial completion • Novel Coronavirus Disease

The NICE-PAD II Trial (clinicaltrials.gov) - P3 | N=250 | Not yet recruiting | Sponsor: Northwestern University

New P3 trial • Cardiovascular • Peripheral Arterial Disease

General Glycosylation for the synthesis of C-Aryl nucleosides by aluminum reagents (ACS-Fall 2026) - "A number of C-nucleosides, such as benzamide riboside, naturally occurring nicotinamide riboside, pseudouridine, showdomycin have been identified as promising lead molecules in the search for antiviral and anticancer drugs...As part of our ongoing research in nucleoside chemistry, we have developed a general and mild C-glycosylation strategy using an aluminum-based reagent system in the presence of a Lewis acid. This methodology transforms imino-, thio-, and ribo-glycosyl donors, under mild reaction conditions, into their corresponding C-linked nucleoside analogues."

NR-RADIANCE: Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging (clinicaltrials.gov) - P=N/A | N=140 | Recruiting | Sponsor: ChromaDex, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

NR-RADIANCE: Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging (clinicaltrials.gov) - P=N/A | N=140 | Not yet recruiting | Sponsor: ChromaDex, Inc.

New trial

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: Donna Hammond, PhD | Trial completion date: Jul 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Breast Cancer • Endometrial Cancer • Oncology

N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease (clinicaltrials.gov) - P2 | N=270 | Recruiting | Sponsor: Haukeland University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • p-tau181

Nicotinamide riboside improves mitochondrial dynamics and reduces superoxide levels in fibroblasts with sulfur metabolism disorders (SSIEM 2026) - "Our findings show that treatment with NR modulated mitochondrial dynamics and reduced superoxide levels in a subset of ETHE1 and MOCS1-deficient cell lines, identifying it as a potential therapeutic candidate for these disorders."

CNS Disorders • Epilepsy • Genetic Disorders • Metabolic Disorders • MOCS1

NAD Supplementation in Parkinson's Disease (clinicaltrials.gov) - P=N/A | N=40 | Enrolling by invitation | Sponsor: University of Oklahoma | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Restorin® NR is a Highly Efficient NAD+ Precursor. (PubMed, Drug Des Devel Ther) - "Among NAD+ precursors, nicotinamide riboside (NR) has attracted interest owing to its potent in vivo NAD+ biosynthetic activity...These results confirm Restorin NR's superiority to the tested precursors for NAD+ concentrations in circulation. Overall, our research identifies a new crystalline salt form of NR and classifies Restorin NR as a promising new therapeutic agent to enhance NAD+ levels and combat aging."

Journal